Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jaceidin is a methoxylated flavonoid naturally occurring in various plant species, including *Varthemia iphionoides* and members of the *Centaurea* genus. It is currently being investigated as a potential lead compound for the treatment of metastatic prostate cancer. Research indicates that jaceidin exhibits cytotoxic activity against cancer cell lines, such as PC3 and DU145, by inducing apoptosis through the depolarization of the mitochondrial membrane and the modulation of cell-cycle dynamics. In silico ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling suggests that jaceidin possesses favorable drug-likeness properties, making it a candidate for further pharmaceutical development as a scaffold for novel antineoplastic therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jaceidin.